Clinical Oncology - 2016;3(01)

Clinical Oncology

FEBRUARY 15, 2016

[Foreword]

A szerkesztők

HUN 2016;3(01)

Clinical Oncology

FEBRUARY 15, 2016

[News from the World]

HUN 2016;3(01)

Clinical Oncology

FEBRUARY 15, 2016

[Prevention and therapy of cervical cancer ]

RÉVÉSZ János, BÍRÓ Mátyás

[The global incidence of cervical cancer is ~530000, the death rate is ~270000 per year. These data shows, that cervical cancer is the fourth common malignancy in woman worldwide and the leading cancer related death in developing countries. HPV infection is the most important factor of carcinogenesis. Immunisation against HPV can prevent infection, and decrease the cancer incidence. In case of invasive cancer the therapeutic principles are surgery and radiotherapy. In case of high risk patients... tovább »

HUN 2016;3(01)

Clinical Oncology

FEBRUARY 15, 2016

[Treatment of mesothelioma - an update]

MOLDVAY Judit, HEGEDŰS Balázs, KOVÁCS Ildikó, DÖME Balázs

[Malignant pleural mesothelioma is an aggressive tumor arising from the mesothelial cells lining the pleura. It is an asbestos related disease with increasing incidence both in Europe and in Hungary. This often fatal disease is characterized by rapid progression, and unfortunately, treatment options are very limited to date. Thus every effort should be made to better understand the pathological and molecular biological characteristics of this disease in order to develop new treatment... tovább »

HUN 2016;3(01)

Clinical Oncology

FEBRUARY 15, 2016

[Follicular lymphoma - a way to personalized and targeted therapy ]

BÖDÖR Csaba, SCHNEIDER Tamás

[Although follicular lymphoma is the most frequent non-Hodgkin’s lymphoma with an indolent clinical course, it is a rare disease. Patients with FL are characterized with a long survival with a relatively good quality of life, however using the current standard chemo-immunotherapy, the disease is considered incurable. The increasing knowledge of the molecular genetic background of the disease and the role of the reactive microenvironment lead to a better understanding of the pathogenesis of... tovább »

HUN 2016;3(01)

Clinical Oncology

FEBRUARY 15, 2016

[Oncogene-targeted therapy of non-small cell lung cancer]

TANJA Cufer

[Lung cancer is the leading cause of cancer related deaths thus presenting one of the main public health related issues globally. Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancer cases. Historically, platinum-based chemotherapy was the mainstay of systemic therapy for NSCLC, leading to median survival rates of only 8 to 10 months. Major improvement in the treatment of NSCLC was made through the identifi cation of key genetic aberrations (oncogene drivers) that... tovább »

HUN 2016;3(01)

Clinical Oncology

FEBRUARY 15, 2016

[Epigenetics and cancer]

KOPPER László

[Epigenetics is concerned with the modulation of the genom without structural changes in the nucleotide-sequence. The main target in the regulation of epigenetical activity is gene expression. The main mechanisms in epigenetics the reversible chemical modulation of the DNA and the histones which are regulated by enzyme-complexes, acting directly with the metabolism and the signaling pathways, as well as with the sensors of macro- and microenvironment. New members of the epigenetical family are... tovább »

HUN 2016;3(01)

Clinical Oncology

FEBRUARY 15, 2016

[Oncotherapy associated skin toxicity]

OLÁH Judit

[The last decades opened a new era of oncotherapy, including the development of targeted therapies for different subtypes of malignancies. Cutaneous adverse events are the most frequent toxicities among side effects of personally tailored molecular targeted agents. This review summarizes the practical aspects of the clinical characteristics and the optimal treatment of skin-related complications caused by oncological drugs.]

HUN 2016;3(01)

Clinical Oncology

FEBRUARY 15, 2016

[Surgical view on the perioperative oncological treatment of liver metastases originated from colorectal cancer]

KUPCSULIK Péter

[Recent development of surgery resulted in fundamental changes in assessment of resectability of liver tumors. Surgical interventions became more radical and more effective. Colorectal liver metastasis (CLM) represents the most frequent hepatic tumor, where therapeutic options require close collaboration between surgeons and oncologists, and up-to-date approach from both. As the fact is, that CLM is a metastasis of a primary colorectal carcinoma, it seems to be obvious to apply perioperative... tovább »

HUN 2016;3(01)